Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone

Transfusion

Volumn 49, Issue 3, 2009, Pages 513-518

  Quillen, Karen ^a,b   Byrne, Phyllis ^b   Yau, Yu Ying ^b   Leitman, Susan F ^b  

^a National Institutes of Health ^*  (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD DONOR; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTAPHERESIS; DEEP VEIN THROMBOSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; GRANULOCYTE TRANSFUSION; HUMAN; LONG TERM CARE; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; THROMBOCYTE COUNT;

ADULT; AGED; BLOOD DONORS; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 60149086306     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01983.x     Document Type: Article

References (27)

1. Caspar C, Seger R, Burger J, Gmur J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993 81 : 2866 71.
2. Liles WC, Huang JE, Llewellyn C, SenGupta D, Price TH, Dale DC. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997 37 : 182 7.
3. Price TH, Bowden RA, Boechkh M, Bux J, Nelson K, Liles WC, Dale DC. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000 95 : 3302 9.
4. Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion 2001 41 : 1037 44.
5. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000 25 : 85 9.
6. Tassi C, Tazzari PL, Bonifazi F, Giudice F, Nannetti A, Ricci F, Rizzi S, Bandini G, Conte R. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005 36 : 289 94.
7. Bux J, Cassens U, Dielschneider T, Duchscherer M, Edel E, Eichler H, Haas C, Moog R, Peschke H, Peters C, Ryzenkov I, Schlenke P, Ullrich H, Wiesneth M. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang 2003 85 : 322 5.
8. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008 111 : 1767 72.
9. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007 40 : 185 92.
10. Stroncek D, Shawker T, Follman D, Leitman SF. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003 43 : 609 13.
11. Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, Galbusera M, Cerletti C, Barbui T. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999 93 : 2506 14.
12. Canales MA, Arrieta R, Gomez-Rioja R, Diez J, Jimenez-Yuste V, Hernandez-Navarro F. Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors. J Hematother Stem Cell Res 2002 11 : 675 81.
13. Shimoda K, Okamura S, Inaba S, Okamura T, Ohga S, Ueda K, Niho Y. Granulocyte colony-stimulating factor and platelet aggregation. Lancet 1993 341 : 633.
14. LeBlanc R, Roy J, Demers C, Vu L, Cantin G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999 23 : 991 6.
15. Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005 46 : 1643 8.
16. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006 46 : 422 33.
17. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004 29 : 439 93.
18. Ofran Y, Avivi I, Oren I, Zuckerman T, Bonstein L, Rowe JM, Dann EJ. Granulocyte transfusions for neutropenic patients with life-threatening infections: a single center experience in 47 patients, who received 348 granulocyte transfusions. Vox Sang 2007 93 : 363 9.
19. Stevens WT, Bolan CD, Oblitas JM, Stroncek DE, Bennett JE, Leitman SF. Streptococcus agalactiae sepsis after transfusion of a plateletpheresis concentrate: benefit of donor evaluation. Transfusion 2006 46 : 649 51.
20. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007 137 : 76 80.
21. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer. J Clin Oncol 2003 21 : 1195 204.
22. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007 99 : 196 205.
23. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006 135 : 642 50.
24. Hasenclever D, Sextro M. Safety of alloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996 17 Suppl 2 : S28 30.
25. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004 32 : 122 30.
26. Hernandez JM, Castilla C, Gutierrez NC, Isidro IM, Delgado M, de las Rivas J, Ferminan E, Garcia JL, Ocio EM, del Canizo MC, San Miguel JF. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005 19 : 1088 91.
27. Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A. Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors. Acta Haematol 2007 117 : 68 73.